Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Influenza virus neuraminidase contributes to secondary bacterial pneumonia.

Peltola VT, Murti KG, McCullers JA.

J Infect Dis. 2005 Jul 15;192(2):249-57. Epub 2005 Jun 8.

2.

Deletions in the neuraminidase stalk region of H2N2 and H9N2 avian influenza virus subtypes do not affect postinfluenza secondary bacterial pneumonia.

Chockalingam AK, Hickman D, Pena L, Ye J, Ferrero A, Echenique JR, Chen H, Sutton T, Perez DR.

J Virol. 2012 Apr;86(7):3564-73. doi: 10.1128/JVI.05809-11. Epub 2012 Jan 25.

3.

Influenza viral neuraminidase primes bacterial coinfection through TGF-β-mediated expression of host cell receptors.

Li N, Ren A, Wang X, Fan X, Zhao Y, Gao GF, Cleary P, Wang B.

Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):238-43. doi: 10.1073/pnas.1414422112. Epub 2014 Dec 22.

4.

[Clinical features and outcome in 84 patients with influenza pneumonia].

Takayanagi N, Hara K, Tokunaga D, Kato T, Kanazawa M, Saito H, Ubukata M, Kurashima K, Yanagisawa T, Sugita Y.

Nihon Kokyuki Gakkai Zasshi. 2006 Oct;44(10):681-8. Japanese.

PMID:
17087332
5.

Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza.

McCullers JA.

J Infect Dis. 2004 Aug 1;190(3):519-26. Epub 2004 Jun 30.

6.

In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication.

Kati WM, Montgomery D, Carrick R, Gubareva L, Maring C, McDaniel K, Steffy K, Molla A, Hayden F, Kempf D, Kohlbrenner W.

Antimicrob Agents Chemother. 2002 Apr;46(4):1014-21.

7.

Enzymological characteristics of avian influenza A virus neuraminidase.

Kiyotani K, Takei N, Senoo M, Takao S, Otsuki K, Tsubokura M, Yoshida T.

Microbiol Immunol. 1987;31(11):1131-5.

8.

Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae.

McCullers JA, Bartmess KC.

J Infect Dis. 2003 Mar 15;187(6):1000-9. Epub 2003 Mar 6.

9.

Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza.

Metersky ML, Masterton RG, Lode H, File TM Jr, Babinchak T.

Int J Infect Dis. 2012 May;16(5):e321-31. doi: 10.1016/j.ijid.2012.01.003. Epub 2012 Mar 2. Review.

10.

[Pneumonia and influenza].

Kawakami K, Nagatake T.

Nihon Rinsho. 2000 Nov;58(11):2249-54. Review. Japanese.

PMID:
11225313
11.

[Antigenic specificity of the neuraminidases of epidemic strains of influenza A/H3N2 viruses circulating in the USSR 1983-1985].

Liubovtseva OV, Iakhno MA, Zakstel'skaia LIa.

Vopr Virusol. 1987 May-Jun;32(3):283-5. Russian.

PMID:
2445104
12.
14.

[Effect of low pH values on the infectivity and neuraminidase activity of human and animal strains of influenza virus type A].

Glathe H, Strittmatter HU, Kunze M, Sinnecker H.

Acta Biol Med Ger. 1982;41(11):1075-8. German.

PMID:
7170871
15.

[Influenza pneumonia].

Zeller V, Bricaire F.

Rev Prat. 2003 Sep 15;53(13):1442-5. Review. French.

PMID:
14558265
16.

Neuraminidase activity is not the cause of influenza virus-induced neutrophil dysfunction.

Abramson JS, Wiegand GL, Lyles DS.

J Clin Microbiol. 1985 Jul;22(1):129-31.

17.

The rapid identification of human influenza neuraminidase N1 and N2 subtypes by ELISA.

Barr IG, McCaig M, Durrant C, Shaw R.

Vaccine. 2006 Nov 10;24(44-46):6675-8. Epub 2006 Jun 8.

PMID:
16860447
18.

Do specific virus-bacteria pairings drive clinical outcomes of pneumonia?

McCullers JA.

Clin Microbiol Infect. 2013 Feb;19(2):113-8. doi: 10.1111/1469-0691.12093. Epub 2012 Dec 10. Review.

19.

Augmented lung inflammation protects against influenza A pneumonia.

Tuvim MJ, Evans SE, Clement CG, Dickey BF, Gilbert BE.

PLoS One. 2009;4(1):e4176. doi: 10.1371/journal.pone.0004176. Epub 2009 Jan 12.

20.

Improving therapeutic strategies for secondary bacterial pneumonia following influenza.

McCullers JA, English BK.

Future Microbiol. 2008 Aug;3(4):397-404. doi: 10.2217/17460913.3.4.397.

Items per page

Supplemental Content

Write to the Help Desk